
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 27, 2010

OPKO Health, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other
Jurisdiction of
Incorporation)

001-33528
(Commission
File Number)

75-2402409
(IRS Employer
Identification No.)

**4400 Biscayne Blvd
Miami, Florida 33137**
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (305) 575-4100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting of Stockholders of the Company held on May 27, 2010, the stockholders elected each of the Company's ten nominees for directors to serve until the Company's 2011 Annual Meeting of Stockholders.

The results of the voting were as follows:

	For	Withheld
Election of Directors		
Phillip Frost, M.D.	202,370,079	1,598,123
Jane H. Hsiao, Ph.D.	199,177,074	4,791,128
Steven D. Rubin	201,944,346	2,023,856
Robert A. Baron	203,524,970	443,232
Thomas E. Beier	202,635,253	1,332,949
Pascal J. Goldschmidt, M.D.	199,334,665	4,633,537
Richard A. Lerner, M.D.	203,549,128	419,074
John A. Paganelli	201,978,601	1,989,601
Richard C. Pfenniger, Jr.	199,918,977	4,049,225
Alice Lin-Tsing Yu, M.D., Ph.D.	199,235,335	4,732,867

No other matters were considered or voted upon at the meeting.

ITEM 8.01 Other Events.

On May 27, 2010, the Company held its Annual Meeting of Stockholders. A copy of management's presentation presented at the Annual Meeting is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Statements made in the presentation which are not historical are forward-looking statements that reflect management's current views with respect to future events and performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions. Such statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The fact that these presentation materials are being furnished should not be deemed an admission as to the materiality of any information contained in the materials.

The information contained in Item 8.01 to this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Act.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Management Presentation — 2010 Annual Meeting of Stockholders held May 27, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

By /s/ Adam Logal

Name: Adam Logal

Title: Executive Director of Finance,
Chief Accounting Officer
Treasurer

Date: June 1, 2010



OPKO

May 27, 2010
Annual Stockholders Meeting



Cautionary Statement

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our ability to develop oral and IV formulations of rolapitant and simple blood tests for neurological disorders, cancers and other disease, our product development efforts and expected timing thereof, the products' potential benefits, statements regarding rolapitant being a best-in-class product, the timing of clinical trials for our product candidates and the commercial launch of rolapitant and our other product candidates, and estimates regarding market potential and timing of regulatory approval for our product candidates, as well as other non-historical statements. These forward-looking statements are only predictions and reflect our views as of the date they were made, and we undertake no obligation to update such statements. Such statements are subject to many risks and uncertainties that could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, the possibility of infringing a third party's patents or other intellectual property rights, the uncertainty of obtaining patents covering our products and processes and in successfully enforcing them against third parties, and the possibility of litigation, among other factors.

OPKO

2



OPKO 2009 Highlights

- 2009 was year of investment and growth as OPKO expanded beyond ophthalmics into areas of major unmet medical need.
 - Acquired two operating companies in Latin America
 - Acquired several important products and technologies
 - Raised \$81 million in capital

OPKO



New Products & Technologies

- Acquired rolapitant and other NK-1 assets from Schering Plough.
 - Phase II clinical testing completed for prevention of chemotherapy induced and post-operative induced nausea and vomiting.
 - Company intends to pursue development for both indications



New Products & Technologies (Cont'd.)

- Acquired rights to a platform technology used to create important new diagnostic tests, vaccines, and therapeutic agents.
 - Presently working to develop simple blood tests for Alzheimer's disease, Parkinson's disease, lung cancer, and others.



New Products & Technologies (Cont'd.)

- Acquired worldwide rights for new technology to develop vaccines against influenza and other viral infections.
- Acquired worldwide rights for new technology to target cancer cells and deliver chemotherapeutic agents to target site.

OPKO



Acquisitions and Investments

- Acquired Pharma Genexx, S.A. in October 2009.
 - Sells broad range of products to private, hospital and institutional Markets in Chile.
- Acquired Pharmacos Exakta, S.A. de C.V. in February 2010.
 - Manufactures, markets and sells broad range of ophthalmic and other pharmaceutical products in private and public markets in Mexico.

OPKO

7



Acquisitions and Investments










- Invested in Sorrento Therapeutics, Inc.
 - 24% owned by OPKO.
 - Became publicly traded in 2009.
 - Recently announced validation of technology to produce larger human antibody libraries more efficiently than presently available methods.



Acquisitions and Investments

- Invested in Cocystal Discovery, Inc.
 - 16% owned by OPKO.
 - Privately held biopharmaceutical company
 - Using novel approach to drug discovery to develop new broad spectrum anti-viral drugs.

OPKO R&D Pipeline

Products	Mode of Action	Indication	Pre-Clinical	Phase I	Phase II	Phase III
Rolapitant	NK1 Receptor Antagonist	Emesis				
Doxovir	Anti-Viral	Viral Conjunctivitis				
Aquashunt	Drainage Shunt	Glaucoma				
Molecular Diagnostics	Identification of Disease Specific Antibodies	Alzheimer's, Parkinson's, Lung Cancer, Pancreatic Cancer				
SCH 900978	NK1 Receptor Antagonist	Emesis				
OPK - 0018	Oral Inhaler/ Disaccharide Anti-Inflammatory	Asthma, COPD and Cystic Fibrosis				
siRNA	Gene Silencing	AMD				
Flu Vaccine	Hemagglutinin	Pan-Influenza (e.g. H1, H3, H5)				
Adjuvant	Immuno-stimulant	Vaccinations, Chemotherapy				

OPKO



Rolapitant Potential Best-in-Class NK-1 Receptor Antagonist

- Rolapitant acquired from Schering-Plough (Nov 2009) related to merger with Merck
- Phase 2 completed for chemotherapy and post-operative N&V (CINV/PONV)
- Successful end of Phase 2 meeting with FDA in April 2010
- Oral and IV formulation in development
- Patent exclusivity for next 15+ years



Rolapitant

Differentiation and Plans

- Key properties that make rolapitant profile better than competition (“best-in-class”)
 - No clinically significant drug-drug interactions
 - Single dose regimen offering durable protection (5 days post dose)
 - First to document sustained benefit of 5 day protection in PONV
- 1st indication CINV with potential launch in next 2-3 years



Influenza

- 200,000 hospitalizations and 46,000 deaths in U.S. each year
- Economic costs in U.S. ~\$80 billion a year
- Annual “flu shot” against common strains
- Flu vaccine grown in chicken eggs
- Limitations:
 - New vaccine each year
 - Only partially protective
 - Manufacturing capacity limited



Universal Flu Vaccine

Preclinical Development

- Universal flu vaccine licensed from Academia Sinica July 20, 2009
- Vaccine based on modified hemagglutinin
- Broad protection against variants
- High potency
- Preclinical development initiated
 - Large-scale manufacturing process being determined



Adjuvant

- Small molecule adjuvant
- Improves the immune response in vaccines
- Enhances the pharmacological effect of chemotherapy agents
- Immunomodulator which suppresses tumors independently



Molecular Diagnostics

Overview

- Global molecular diagnostic market projected to reach ~\$4B by 2010
- Largest growth segments
 - 1) Early detection
 - 2) Companion diagnostics



Molecular Diagnostics

Small Molecule Microarray

- Molecular microarray technology acquired June 2009
- **“Peptoids”** as first example of small molecule to detect **disease-associated antibodies**
- Broad application for diagnosing diseases by a simple blood test
 - Neurological disorders (Alzheimer's Disease, Parkinson's)
 - Cancers (e.g. Lung, Pancreatic)
 - Other Diseases



Asthma & COPD

- Over 22 million in the U.S. live with asthma, including more than 6 million children
- There are more than 11 million in the U.S. who have COPD
- Various drug treatments are available, but often with unwanted side effects and/or limited effectiveness
- Asthma & COPD Global Market was approximately U.S. \$28 billion in 2007




Lead Compound – OPK -0018

- Novel Heparin-Derived Oligosaccharide Anti-Inflammatory Agent
 - Heparin is a polysaccharide discovered in 1927 as an anticoagulant
 - Heparin has been shown to have anti-inflammatory actions in a range of human disease but its anti-coagulant actions limit its use
- Multiple patents issued claiming various oligosaccharides and disaccharides and additional patents pending claiming specific formulations and uses
- In vivo anti-inflammatory/anti-allergic efficacy demonstrated in sheep and mice
- Effective orally inhaled with inhaler or nebulizer
- Phase 1 trials of two, single dose aerosol safety studies completed

OPKO Instruments

Integrated OCT and SLO

- OCT and SLO from single source
 - Precise pixel-to-pixel correlation of coronal OCT slice to SLO surface image
 - Ultra-high resolution imaging of eye
- Diagnosis of retinal and other eye diseases



OCT=Ocular coherence tomography
SLO=Scanning laser ophthalmoscopy



OPKO Summary

- Rapid expansion of drug development portfolio, including late stage compounds
- Profitable pharmaceutical companies acquired
- Minority interest in high potential biotechnology companies